Literature DB >> 32627125

Expression of tissue factor mRNA in thrombosis associated with antiphospholipid syndrome.

Bruna de Moraes Mazetto1, Mariana Lazarini2, Lais Quinteiro Tobaldini1,2, Fernanda Talge Arantes1,2, Ana Paula Rosa Dos Santos1,2, Bruna Cardoso Jacinto1,2, Camila de Oliveira Vaz1,2, Gabriela Tripiquia Vechiatto Mesquita1,2, Sabrina da Silva Saraiva1,2, Joyce Annichino-Bizzacchi2,3, Fernanda Andrade Orsi4,5.   

Abstract

Tissue factor (TF) is a procoagulant protein associated with increased risk of thrombotic events in antiphospholipid syndrome (t-APS). The mechanisms by which TF levels are increased in APS have not yet been established. The aim of this study was to investigate whether TF mRNA expression is associated with TF levels and thrombosis in APS. We compared levels of circulating TF and high sensitivity C-reactive protein (hs-CRP) between t-APS and controls (individuals without thrombosis). The association between TF mRNA expression, quantified by real time quantitative polymerase chain reaction, and t-APS was accessed using regression analysis. We included 41 controls and 42 t-APS patients, mean age was 41 years old (SD 14) in both groups. Hs-CRP and TF levels were higher in t-APS patients (mean hs-CRP levels 0.81 mg/dL [SD 1.88] and median TF levels 249.0 pg/mL [IQR 138.77-447.61]) as compared to controls (mean hs-CRP levels 0.24 mg/dL [SD 0.26] and median TF levels 113.0 pg/mL [IQR 81.17-161.53]; P = 0.02 and P < 0.0001, respectively). There was no correlation between TF mRNA expression and TF levels in t-APS (r - 0.209, P = 0.19). TF mRNA expression was not associated with t-APS (adjusted OR 1.16; 95%CI 0.72-1.87). Despite circulating TF levels being higher in patients with t-APS than in controls, TF mRNA expression was similar between groups. The results demonstrate that TF mRNA expression is not associated with levels of circulating TF and hypercoagulability in t-APS.

Entities:  

Keywords:  Antiphospholipid; Coagulation; Thrombosis; Tissue factor; mRNA

Year:  2021        PMID: 32627125     DOI: 10.1007/s11239-020-02209-1

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  52 in total

Review 1.  Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature.

Authors:  Monica Galli; Davide Luciani; Guido Bertolini; Tiziano Barbui
Journal:  Blood       Date:  2002-10-03       Impact factor: 22.113

2.  International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).

Authors:  S Miyakis; M D Lockshin; T Atsumi; D W Branch; R L Brey; R Cervera; R H W M Derksen; P G DE Groot; T Koike; P L Meroni; G Reber; Y Shoenfeld; A Tincani; P G Vlachoyiannopoulos; S A Krilis
Journal:  J Thromb Haemost       Date:  2006-02       Impact factor: 5.824

3.  Circulating tissue factor accumulates in thrombi, but not in hemostatic plugs.

Authors:  M Hoffman; H C Whinna; D M Monroe
Journal:  J Thromb Haemost       Date:  2006-09       Impact factor: 5.824

4.  The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome.

Authors:  O Amengual; T Atsumi; M A Khamashta; G R Hughes
Journal:  Thromb Haemost       Date:  1998-02       Impact factor: 5.249

5.  Hypercoagulable state in patients with antiphospholipid syndrome is related to high induced tissue factor expression on monocytes and to low free protein s.

Authors:  J C Reverter; D Tàssies; J Font; J Monteagudo; G Escolar; M Ingelmo; A Ordinas
Journal:  Arterioscler Thromb Vasc Biol       Date:  1996-11       Impact factor: 8.311

6.  beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome.

Authors:  H Bas de Laat; Ronald H W M Derksen; Rolf T Urbanus; Mark Roest; Philip G de Groot
Journal:  Blood       Date:  2004-08-17       Impact factor: 22.113

7.  Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep.

Authors:  Hong Zhou; Alisa S Wolberg; Robert A S Roubey
Journal:  Blood       Date:  2004-06-29       Impact factor: 22.113

8.  Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein.

Authors:  Vladimir Y Bogdanov; Viji Balasubramanian; James Hathcock; Oana Vele; Mark Lieb; Yale Nemerson
Journal:  Nat Med       Date:  2003-03-24       Impact factor: 53.440

Review 9.  The role of the tissue factor pathway in haemostasis and beyond.

Authors:  John H McVey
Journal:  Curr Opin Hematol       Date:  2016-09       Impact factor: 3.284

10.  Phospholipid Binding Protein C Inhibitor (PCI) Is Present on Microparticles Generated In Vitro and In Vivo.

Authors:  Katrin Einfinger; Sigrun Badrnya; Margareta Furtmüller; Daniela Handschuh; Herbert Lindner; Margarethe Geiger
Journal:  PLoS One       Date:  2015-11-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.